The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.’s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. • DNLI is in negative territory. Track the latest developments here.The Prescription Drug User Fee Act (PDUFA) target date has been extended from Jan. 5, 2026, to April 5, 2026.Also Read: Denali Therapeutics Ends ...

Core Viewpoint - Biohaven's main asset, Troriluzole, is under FDA review and has the potential for approval, which is a key driver for the company's stock performance [1] Group 1: Investment and Financial Support - Oberland Capital Management plans to inject up to $600 million into Biohaven, structured through milestone payments and royalties based on Troriluzole's future net sales [1] - Citigroup has assigned a "Buy" rating to Biohaven with a target price of $28 per share [1] Group 2: Regulatory Developments - The FDA recently canceled a planned advisory committee meeting for Troriluzole's marketing application for treating Spinocerebellar Ataxia (SCA), with the PDUFA target action date set for the fourth quarter [1] - The likelihood of Troriluzole receiving FDA approval is assessed to be over 50% based on clinical data, regulatory precedents, and the investment decision by Oberland Capital [1] Group 3: Stock Performance and Valuation - Biohaven's stock has declined nearly two-thirds over the past 12 months, with current valuations reflecting the risks associated with the PDUFA approval [2] - If Troriluzole is approved, significant upside potential for Biohaven's stock price is anticipated [2] - On Wednesday, Biohaven's stock rose by 8.97% to $14.7, with an after-hours increase of 4.42% to $15.35 [2]

Financial Data and Key Metrics Changes - The company received approval for Midaso or Dodavapene ahead of the PDUFA date, indicating strong progress in regulatory interactions with the FDA [4] - Strong results were reported for Xywav, with approximately 400 net patient additions in the second quarter for idiopathic hypersomnia, where it is the only approved treatment [6][7] Business Line Data and Key Metrics Changes - Xywav continues to perform well in both idiopathic hypersomnia and narcolepsy, with significant growth driven by the unique low sodium formulation that appeals to patients and physicians [15][17] - The oncology segment is seeing exciting developments, particularly with the upcoming Zepzelca approval and ongoing trials for Zanidatamab, which is expected to yield important data in the fourth quarter of 2025 [9][10] Market Data and Key Metrics Changes - The market for small cell lung cancer is becoming more competitive, but the company is optimistic about Zepzelca's potential in both first-line and second-line settings [50][51] - The company is preparing for potential competition from generics in the oxybate market, particularly with the anticipated introduction of generic Xyrem in early 2026 [19][20] Company Strategy and Development Direction - The company is focused on driving value through its existing assets while exploring new opportunities in rare oncology and epilepsy [56] - The new CEO, Renée Galá, is expected to bring fresh insights and leadership to further the company's strategic goals [6][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming clinical data and the potential for both Zanidatamab and Dodavapene to change the standard of care in their respective indications [57][58] - The company is prepared for various market scenarios, particularly regarding the impact of generics on its revenue streams [19][20] Other Important Information - The company has completed a licensing transaction to enhance its epilepsy franchise, indicating a proactive approach to expanding its portfolio [5] - Management emphasized a disciplined approach to managing expenses while investing in high-potential R&D opportunities [53][54] Q&A Session Summary Question: How is Xywav performing amidst competition? - Management noted that Xywav has shown strong growth, particularly in idiopathic hypersomnia, and they expect this trend to continue [15][17] Question: What are the expectations regarding generics entering the market? - Management is planning for various scenarios, including the potential impact of generics on revenue, and is prepared to adapt to market conditions [19][20] Question: How does the company view the competitive landscape for Durexins? - Management sees Durexins as a potent adjunctive therapy for narcolepsy, which could improve patient outcomes without replacing oxybate therapy [25][26] Question: What is the outlook for Zanidatamab's clinical trials? - Management is optimistic about the upcoming data readouts and believes the active arms of the trial could perform better than initially anticipated [29][30] Question: How is the company managing operating expenses while pursuing growth? - Management emphasized a focus on high-impact investments in R&D while maintaining tight control over SG&A expenses [53][54]

Core Viewpoint - Biohaven's stock experienced significant volatility, dropping nearly 20% due to a regulatory delay regarding its promising drug, trotziluzole, despite a generally positive market day for other stocks [1][2]. Regulatory Update - The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Biohaven's drug, troriluzole, by three months, with a new decision expected in the fourth quarter of this year [4]. - The extension is due to the FDA's need for additional time to review recent submissions from Biohaven [5]. Drug Potential - Troriluzole targets spinocerebellar ataxia (SCA), a rare brain disorder with no current treatment options, and has received fast-track, priority review, and orphan drug designation from the FDA [6]. - Investor sentiment remains optimistic about the drug's potential, although the delay has raised concerns about the future approval process [7].